ArticleCells2026
Serum from Fibromyalgia Patients Activates Satellite Glial Cells in Mouse Peripheral Ganglia.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fibromyalgia (FM) is a complex syndrome associated with chronic widespread pain and with various other symptoms, including sleep and mood disturbances. Its underlying causes are not fully understood, and the lack of diagnostic blood tests and imaging, along with the absence of definitive treatments, makes management challenging. Recent studies showed that passive transfer of immunoglobulins from FM patients into mice activated satellite glial cells (SGCs) in mouse dorsal root ganglia (DRG), leading to pain behaviors. Here, we aimed to determine whether whole serum from FM patients activates mouse SGCs in DRGs and other ganglia that may be involved in FM's diverse symptoms. Serum from FM patients (N = 15) and healthy controls (HCs, N = 8) was collected. Sera were incubated with different types of mouse sensory ganglia: DRG, trigeminal ganglion (TG), the nodose ganglion (NG), and the superior cervical sympathetic ganglion (Sup-CG). SGC activation was assessed by immunostaining of SGCs for the glial activation marker glial fibrillary acidic protein (GFAP). All the ganglia tested, DRG, TG, NG, and Sup-CG, displayed induced upregulation of GFAP labeling in SGCs after incubation with FM serum compared with HCs, indicating SGC activation by the serum. Similar responses were observed in both male and female mice. We conclude that serum from FM patients contains factors that can activate SGCs across various types of mouse ganglia, which may reflect the diverse symptom profile of FM. These findings provide evidence for pathogenic factors that could serve as a foundation for a diagnostic method for FM and require further purification and identification, hopefully paving the way for future targeted FM therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.